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[57] ABSTRACT
Thepresent invention involves a method for preparing
antibody-producing chicken cell clones. This method
comprises a series-of steps including initially immuniz-
ing a first chicken with a desired antigen. A population
of antibody-producing lymphocytes from bursa or
spleen ofthe first chicken is separated.
The antibody-producing lymphocyte population is then
infected with helper-free reticuloendotheliosis virus
REV-T or helper-free . reticuloendotheliosis virus
REV-T and CSV (preferably REV-T(CSV)and trans-
planted into a second chicken, the second chicken hav-
ing been pretreated to remove normal B cells. The
transplanted lymphocytes to proliferate in the second
chicken, preferably for a period of at least about two
weeks.
The lymphocytes from spleen, bursa or peripheral
blood of the second chicken are isolated and plated out,
for example in microtiter plates. Cell clones producing
antibody such as IgG or IgM directed against the de-
sired antigen are then selected. Theisolation step most
preferably involves cell culturing in the .microtiter
plates for a.period of at least about one week.
25 Claims, 8 Drawing Sheets
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5,028,5401
AVIAN IMMUNOGLOBULIN-PRODUCING CELLLINES
Workrelating to the present invention was partially
supported by Public Health Service award CA41450
from the National Institutes of Health.
This is a continuation-in-part of U.S. patent applica-
tion Ser. No. 07/140,263,filed Dec. 31, 1987 pending,
allowed.
BACKGROUNDOF THE INVENTION
Reticuloendotheliosis viruses (REVs) are a group of
avian retroviruses that infect chickens, turkeys, and
ducks (1). The prototype virus of this groupis reticulo-
endotheliosis virus strain T(REV-T). REV-T(REV-A)
designates a mixture of a replication-defective virus
(REV-T) that induces acute neoplastic disease and a
nondefective helper virus (REV-A)capable of inducing
an immunosuppressive runting disease (2-4). REV-A
and other non-defective REVs can be distinguished
from REV-Tbytheir ability to replicate in vitro -in
fibroblasts and their inability to induce acute neoplastic
disease in vivo (5, 6). Some non-defective REVs, chick
syncytial virus (CSV) and REV-A, induce a bursal-
dependent B-cell lymphoma thatis indistinguishable
from avian leukosis virus (ALV)-induced lymphoid
leukosis (6, 7). These tumors developafter a long latent
period, are monoclonal and are characterized by provi-
ral insertion within the c-myc locus (8, 9). In contrast,
REV-T causes an acute neoplastic disease known as
reticuloendotheliosis because the prominentcell in the
original neoplastic lesion was morphologically identi-
fied as reticuloendothelial (10). These tumors develop
rapidly, appear to ‘be polyclonal and are thought to
require the expression of the v-rel oncogene carried by
REV-T (il, 12).
Despite the original description of the disease, the
identity of the tumor induced by v-rel remains unclear.
In situ characterization of the in vivo-derived tumor
tissue has not been reported. In vitro studies suggest the
REV-T-transformed cells are of early lymphoid origin
(13, 14), but the absence of specific markers that define
this phenotype has prevented conclusive identification.
There are. two reports of REV-T-derived cell lines
which express IgM (14, 15) andit is possible that several
phenotypically distinct cells may serve as target cells
for v-rel-induced tumors.
REV-Ais known to cause thymic and bursal atrophy
as well as immunosuppression (2, 17, 18). Since the
bursa is the major compartmentofB lymphocyte devel-
opment in the chicken, we reasoned that one conse-
quence of REV-Ainfection and the subsequent disrup-
tion of this organ mightbe a reduction in B-cell prolifer-
ation and differentiation. If REV-T induces lymphoid
tumors as suggested by studies of in vitro-derived’
REV-T cell lines, it is possible that REV-A replication
influences the spectrum of lymphoid tumors that de-
velop by reducing the pool of IgM positive B-lym-
phocytes that are available for REV-T infection.It has
been reported that both immunosuppression and bursal
atrophy are less severe in CSV-infected chicks (6, 18).
We speculated, therefore, that if CSV provided the
helper virus functions required for REV-T replication,
the poolofcells available for infection by REV-T might
contain significantly more IgM positive lymphocytes.
Since IgM-positive tumorcell lines have been isolated
following REV-T(REV-A)infection, albeit rarely, the
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present invention involves a prediction that REV-
T(CSV)infection would lead to high frequency pro-
duction of IgM positive B-cell lymphomas.
SUMMARYOF THE INVENTION
The present invention involves a method for prepar-
ing antibody-producing avian cell clones. This method
generally comprises: immunizing a first bird with a
desired antigen; separating a population of antibody-
producing B-lymphocytes from the first bird; treating
the antibody-producing B-lymphocyte population with
v-rel under conditions inducing transformation; trans-
planting treated B-lymphocytes into a second bird, the
second bird having been pretreated to remove normal
B-lymphocytes, and allowing transformed B-lym-
phocytesto proliferate in the second bird; and isolating
transformed B-lymphocytes from the second bird.
Theisolating step may involve plating out said trans-
formed B-lymphocytes and/or selecting cell clones
producing antibody directed against the desired anti-
gen. Theisolating step may also involve panning said
transformed B-lymphocyteson a solid surface compris-
ing bound antibodies having binding specificity for the
avian antibody being producedorits isotype.
The population of antibody-producing B-lym-
phocytesare usually separated from the bursa or spleen
of the first bird. The isolation step is defined further as
preferably involving cells from the spleen, bursa or
peripheral blood of the second bird.
For purposes ofpracticing the methodofthe present
invention, the v-rel oncogene is usually included in a
reticuloendotheliosis virus, although transfection meth-
odssuch as electroporation not involving virus may be
used to transform B-lymphocytes.
In the general practice of the present invention, the
birds are preferably chickens and the avian cell clones
are chicken cell clones.
In greater particularity, the present invention in-
volves a method for preparing antibody-producing
avian cell clones comprising: immunizing a first bird
preferably between about six weeks and two years of
age, with a desired antigen, the immunizationofthefirst
bird being preferably monitored by routine serological
analysis; separating a population of antibody-producing
B-lymphocytes from thefirst bird; infecting the anti-
body-producing lymphocyte population with helper-
free reticuloendotheliosis virus or reticuloendotheliosis
virus and helpervirus; transplanting the infected B-lym-
phocyte population into a second bird, the second bird
being preferably between about one week and about
sixteen weeks of age, and having been pretreated, for
example with cyclophosphamide, to remove normal
B-lymphocytes, and allowing the infected B-lym-
phocytesto proliferate in the secondbird; and isolating
infected B-lymphocytes from the second bird. The
transplanted B-lymphocytes are generally allowed to
proliferate for at least about two to three days in the
second bird.
Again, the infected B-lymphocytes are isolated from
the spleen, bursa, bone marrow, liver or peripheral
blood of the second bird. The infected B-lymphocytes
are isolated by a process involving plating out said
isolated B-lymphocytes and selecting cell clones pro-
ducing antibody directed against the desired antigen.
Thebirds are preferably again chickens and the avian
cell clones are chicken cell clones. The population of
antibody-producingcells is preferably separated from
the bursa or spleen ofthefirst bird. The immunization
5,028,540
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of the first bird is indicated by measurement of an anti-
body titer of greater than about 1/200.
The methodsofthe present invention, in one embodi-
ment, preferably involve the separation of antibody-
producing B-lymphocytes by centrifugation in a density
gradient comprising polysaccharide. The antibody pro-
duced by the methodsof the present invention may be
IgM,IgG or IgA, depending upon the lymphocytic cell
types being transformed by v-rel. The isolation step of
the present invention preferably involves plating cells
out in microtiter plates in techniques well-known to
those skilled in the arts. The methods of the present
invention preferably use an isolation step involveing
ceil culturing in microtiter plates for a period ofat least
about one week.
In the processes of the present invention, the combi-
nation of helper-free reticuloendotheliosis virus and
helpervirus is designated REV-T(CSV) andthe helper-
free reticuloendotheliosis virus is REV-T. While the
most preferred helper virus of the present invention is
chick syncytial virus (CSV), the helper virus may also
be spleen necrosis virus (SNV), attenuated REV-A or
duck infectious anemia virus (DIAV). These helper
viruses, which are nontoxic to B-lymphocytes, allow
the incorporation of v-rel and resultant transformation
therebyto facilitate creation of antibody-producing and
long lived cell clones.
Another embodiment of the present invention in-
volves a second method for preparing antibody-produc-
ing avian cell clones. The second method comprising a
sequence of steps analogous in part to the methods
described above. A bird is initially immunized with a
desired antigen by the usual means. Thebird is prefera-
bly a chicken and between about six weeks and two
years of age. The immunization ofthe birdis preferably
monitored by routine serological analysis, a proper
immunization being indicated by measurement of an
antibody titer greater than about 1/200.
A population of antibody-producing B-lymphocytes
is then separated from said bird. 41. The antibody pro-
ducedis preferably of an IgG, IgM or IgG isotype. The
separating step may involve, for example, panning said
antibody-producing B-lymphocytes on a solid surface
comprising bound antibodies having binding specificity
for avian IgM, IgG or IgA. This separation of antibody-
producing B-lymphocytes may involve centrifugation
in a density gradient comprising polysaccharide. This
population of antibody-producing B-lymphocytes is
preferably from bursa, spleen, bone marrow, gland of
Harder,intestinal lining or peripheral blood of the bird.
The separated antibody-producing B-lymphocyte
population is the treated with v-rel under conditions
inducing transformation suchas by transfection with or
electroporation-induced entry of an agent containing a
v-rel gene. The antibody-producing lymphocyte popu-
lation may be treated, for example, with helper-free
reticuloendotheliosis virus .or reticulo-endotheliosis
virus and helper virus to induce such cell transforma-
tion. The v-rel oncogeneis characteristically included
in a reticuloendotheliosis virus. The helper-free reticu-
loendotheliosis virus is preferablyt REV-T and the
reticulo-endotheliosis virus with a helper virus is REV-
T(CSV). The preferred helper virus is chick syncytial
virus (CSV), although spleen necrosis virus (SNV),
attenuated REV-A or duck infectious anemia virus
(DIAV) may beused.
The treated B-lymphocyte population is then incu-
bated in vitro under conditions facilitating proliferation
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of antibody-producing B-lymphocytes transformed by
v-rel. This incubating step may comprise treatment of
the treated B-lymphocyte population with the desired
antigen and subsequentplating in microtiter plates. This
step may also involve incubation of the treated B-lym-
phocyte population in culture medium comprising the
desired antigen and/or B-cell mitogens. The B-cell mi-
togens may be one or moreoflectins, cytokines and
antibodies directed against B-lymphocyte surface pro-
tein.
A preferred additional step involving isolation of
antibody-producing clones is often utilized. This final
step characteristically involves plating out transformed
B-lymphocytes following the incubating step. Such an
isolating step involves selecting cell clones producing
antibody directed against the desired antigen. Such a
selection may be readily accomplished by a procedure
involving panning said transformed B-lymphocytes on a
solid surface comprising a bound second antibody hav-
ing a specific binding specificity an avian antibodyfol-
lows the incubating step.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a comparison of normal, REV-A,and
CSV-infected bursal tissues. Bursal tissue from 2 week
old normal, REV-A, and CSV-infected chicks was
fixed in 10% neutral buffered formalin and processed
for histological examination. Paraffin blocks were sec-
tioned at 5 um and slides were stained with hematoxy-
lin-eosin (A, B, and C). Bursal tissue from 4 week old
chicks was snap-frozen in 2-methylbutane at —70° C.
and sectioned at 8 pm. Slides were stained to reveal
IgM expression using the PAP assay (D, E, and F). A
and D) Normalbursa, B and E) REV-A-infected bursa,
C and F) CSV-infected bursa.
FIG. 2 shows IgM expression in normal, REV-A,
CSV, and ALV-infected splenic tissues. Spleens from 2
week old chicks were snap-frozen in 2-methylbutaneat
—70° C. and sectioned at 8 jum. Slides were stained to
reveal IgM expression using a PAP assay. A) Normal
spleen, B) REV-A-infected spleen, C) CSV-infected
spleen, and D),.ALV-infected spleen. Arrows mark
Schweigger-Seidel sheaths and arrowheads indicate
plasmacells.
FIG. 3 shows expression of REV-A and CSVviral
antigens in infected bursal tissue. Frozen sections of
bursal tissue from 4 week old chicks were stained in a
PAPassay with monoclonal antibody 11A25,. which
recognizes both REV-A and CSV antigens. A) Normal
bursa, B) REV-A-infected bursa, and C) CSV-infected
bursa.
FIG. 4 shows incidence of transformed follicles in
REV-A and CSV-infected chicks. SC chicks were in-
fected with 105ITU REV-A or CSV on day1 after hatch
and sacrificed at 1, 2, and 4 weekspost infection. Bursae
were fixed in 10% neutral buffered formalin and pro-
cessed for histological examination. Serial sections were
prepared throughout the entire bursa at 200 pm inter-
vals, stained with methyl green pyronin, and examined
for the presence of transformed follicles. Each symbol
represents the numberof transformed follicles in a sin- ~
gle bursa. Open symbols (0) represent CSV-infected
bursae and closed symbols. (.)) represent REV-A-
infected bursae.
FIG. 5 showsexpression of IgM in REV-T(REV-A)
and REV-T(CSV)-induced tumors. Adjacent serial
sections of normal, REV-T(REV-A), and REV-
T(CSV)-infected livers prepared from tissue frozen at 1
5,028,5405
week post infection were stained (i) with hematoxylin-
eosin or (ii) with an antilgM monoclonal antibody.
Hematoxylin-eosin stains of A) normal liver, B) REV-
T(REV-A)-infected liver, and C) REV-T(CSV)-
infected liver can be compared with PAPstains for IgM
of D) normalliver, E) REV-T(REV-A)-infected liver,
and F) REV-T(CSV)-infected liver. Arrows indicate
non-tumor markers that allow correct orientation of the
adjacent sections.
FIG. 6 shows analyses of the endogenous viral loci
present in tumorsisolated following transplantation of
REV-T(CSV)-infected bursal lymphocytes. Cellular
DNA was prepared from cell lines developed from
tumors of cytoxan-treated birds repopulated with REV-
T(CSV)-infected bursal lymphocytes. DNAs were di-
gested with Eco RI and analyzed on 0.7% agarose gels,
blotted to nitrocellulose, and hybridized with pBB-12
32P.DNAin order to identify the endogenousviral loci
present. Lanes 1) RBC DNAfrom a donorbird, 2) RBC
DNAfrom a recipient bird, 3-10 DNAsfrom cell lines
derived from tumors of a recipient bird. The cell lines
were derived from liver nodules (lanes 3- 6), bursa (lane
7), thymus (lane 8), and spleen (lanes 9 and 10). Molecu-
lar weight markers are indicated in kilobasesat the left
and EV loci are designated at the right. The EV-4 frag-
ment is 10 Kb and the EV-1 is 8.7 Kb.
FIG. 7 shows analyses of v-rel sequences in tumors
isolated following transplantation of REV-T(CSV)-
infected bursal lymphocytes. Cellular DNA waspre-
pared from cell lines developed from tumors of cytox-
an-treated birds repopulated with REV-T(CSV)-
infected bursal lymphocytes. DNAswere digested with
Bgl Il, analyzed on 0.7% agarose gels. After electro-
phoresis, DNA was blotted to nitro-cellulose and hy-
bridized with pKW101 32P-DNAin order to identify
the REV-Tintegration sites. Lanes 1) RBC DNA from
a donorbird, 2) RBC DNAfroma recipientbird, 3-10)
DNAsfrom cell lines derived fromtumorsofa recipi-
ent bird. The cell lines were derived from liver nodules
(lanes 3-6), bursa (lane 7), thymus (lane 8), and spleen
(lanes 9 and 10). Molecular weight markers are indi-
cated in kilobases at the left and REV-Tspecific inte-
gration sites are marked with asterisks (*). Sizes of
REV-T specific integration fragments range from >23
Kbto 3.7 Kb.c-rel fragments are 15, 9, and 6 Kb and are
indicated with arrowheadsat the right.
DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention involves a method for prepar-
ing antibody-producing chicken ceil clones. This
method comprises a series of steps including initially
immunizing a first chicken with a desired antigen. A
population of antibody-producing lymphocytes from
the bursa or spleen of the first chicken is separated. The
separation of antibody-producing lymphocytesprefera-
bly involves centrifugation in a density gradient com-
prising a polysaccharide such as FICOLL (Pharmacia).
Additionally, the purification may involve binding of
specific lymphocyte populations by employment of
specific monoclonal antibodies in a panning procedure.
Thefirst chicken is preferably between aboutsix and
eight weeks of age. The immunizationstatusofthefirst
chicken is determined by routine serological analysis,
for example, by measurement of an antibody titer of
greater than about 1/200. The antibody-producing lym-
phocyte population is then infected with either helper-
free reticuloendotheliosis virus [REV-T] or reticuloen-
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dotheliosis virus and the helper virus chick syncytial
virus CSV (designated REV-T(CSV))andtransplanted
into a second chicken, the second chicken having been
pretreated to remove normal B cells. The population ofinfected lymphocytes might be prepared by infection of
the cells with REV-T prepared with either CSV or
other helper viruses such as duck infectious anemiavirus “DIAV”attenuated REV-A or spleen necrosis
virus “SNV” (1). The transplanted lymphocytes are
permitted to proliferate in the second chicken, prefera-
bly for a period of at least at least about two to three
days.
The second chicken is preferably between aboutsix
and eight weeks of age and is pretreated with cyclo-
phosphamide to remove normal B cells. The lympho-
cytes from spleen, bursa or peripheral blood of the
second chicken are isolated and plated out, for example
in microtiter plates. Cell clones producing antibody
such as IgG, IgA or IgM directed against the desired
antigen are then selected. The isolation step most pref-
erably involves cell culturing in the microtiter plates for
a period of at least about one week.
CELLS AND VIRUSES
SC chicken embryo fibroblasts (CEF) were cultured
in plastic dishes (Nunc, Denmark) in ET1oCa1o [Dulbec-
co’s modified Eagle’s medium (DMEM,Flow Labora-
tories, McLeon, VA) containing 10% tryptose phos-
phate broth and 10% calf serum (Hazelton, Lenexa,
KA)with antibiotics].
REV-A was rescued by calcium phosphate transfec-
tion of CEF with pSW253 provided by Dr. H. Temin
(12). Transfected celis were cultured and transferred
twice. Medium was harvested at 3 hourintervals from
confluent plates, clarified by centrifugation at 250g,
passed through a 0.2 pm Nalgenefilter, and stored at
-70° C.
CSV(CN19691)-infected line 0 cells were provided
by Dr. R. L. Witter. Culture medium from these cells
was used to infect SC CEF and CSVstocks werepre-
pared as for REV-A.
_ A REV-T nonproducercell line developed in the
laboratory of Dr. H. Bose by in vitro infection of spleen
cells (14) was grown in ET;9Caio Ck2 [ET10Cajo plus
2% chick serum (GIBCO,GrandIsland, N.Y.)]. Stocks
of REV-T(CSV) were made by infecting the REV-T
nonproducer line with CSV and harvesting virus as
aboveafter several cell transfers.
REV-T(REV-A)was harvested from a clone of the
bone marrowcell line isolated in the laboratory of Dr.
H. Bose (19).
The REV-T(REV-A) described herein can be ob-
tained from the American Type Culture Collection as
ATCC VR-770 (strain T).
The REV-A described herein can be obtained from
REV-T(REV-A)by end-point dilution to isolate infec-
tious REV-A free of REV-T using techniques knownto
one skilled in the art and as described (4).
The CSV described herein can be obtained from the
American Type Culture Collection as ATCC VR-588
(strain 9437).
The REV-T(CSV)described herein can be prepared
by using REV-T(REV-A) to isolate a non-producerREV-T-transformed chicken cell line using techniques
known to one skilled in the art and as described (14).
The isolated non-producer REV-T-transformed cell
line is then infected with CSV to produce cells that
release REV-T(CSV).
5,028,5407
Chickens and virus infections
Embryonated SC eggs were purchased from Hyline
International Hatcheries, West Des Moines, Iowa andincubated with humidity at 39° C. On day 1! after hatch,
chicks were infected via intrajugular injection with 105
IU of REV-A, CSV, or REV-T per bird. The chicks
were housed by the Animal Resource Center, Univer-
sity of Texas Health Science Center at Dallas, in rooms
isolated from control or avian leukosis virus-infected
chicks. CSV and REV-A-infected chicks were housed
in separate cages in the sameisolation unit. Food and
water were provided ad lib. For repopulation studies,
recipient chicks were injected intraperitoneally with 3
mg Cytoxan (cyclophosphamide, Mead Johnson, Syra-
cuse, N.Y.) daily for 4 days after hatching to eliminate
the resident B-cells (20). On the sixth day post hatch,
sibling donor chicks were sacrificed by cervical dis-
placement and their bursae were surgically removed.
Bursae were then rinsed in DMEM plusantibiotics and
minced with scissors. A single cell suspension which
was >95% positive for Ig expression was prepared
from bursal pieces and washed once with medium be-
fore resuspension in 2 ml of REV-T(CSV) per 5x 107
cells (moi of 0.05 for REV-T). Cells were incubated
with virus for 15 min on ice followed by 45 min at 37°C. to permit virus absorption and penetration. After one
wash with medium, 5 x 106 of the infected bursalcells
were injected via the jugular vein into cytoxan-treated
recipients.
Sample Collection
Hematocrit samples were obtained from the wing
vein and plasma was collected from the jugular vein and
prepared as previously described (21). After sacrifice,
the bursa, spleen, liver, and heart were excised and
weighed as whole organs. The uppermost bilateral
lobes of the kidney and 7 lobes of the thymus were
excised for weighing in lieu of the total organs since
complete recovery of these organsis difficult and prone
to error. After the organs were weighed, samples for
histology were fixed in 10% neutral buffered formalin
and samples for immunohistochemistry were snap-
frozen in 2-methylbutane at —70° C.
Cell line Isolation
Cell lines were isolated by preparing single cell sus-
pensions from nodulesin the liver and random sections
of tissue from the spleen, thymus, and bursa. These
suspensions were diluted into Hahn’s medium (22) and
cultured at 37° with 10% CO:for 48 hrsbefore transfer-
ring culturesat a 1:5 dilution into ET;9Cajo Ck2. Spleen
and liver cultures were transferred at a 1:10 dilution
every 24 to 48 hours thereafter. Bursa and thymus cul-
tures required more time before the initial transfer;
however, after the second or third transfer, these lines
also required daily transfer. Liver suspensions were
tested at the initial isolation for IgM expression by im-
munofiuorescence, and all lines were assayed by the
fourth or fifth transfer. Cellular DNA wasisolated by
the sixth cell transfer.
Virus Titrations
REV-A and CSV stocks were titrated by endpoint
dilution onto SC CEFcultures as described previously
(21). The REV-A titer was 2X 106IU/ml and the CSV
titer was 1.5106 IU/ml. We have experienced diffi-
culty in establishing a reliable and quantitative in vitro
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assay for REV-T using standard methods (4). Thetiter
of infectious REV-T relative to the infectious titer of
REV-A or CSV was determined by comparing the
amount of REV-T RNA with that of the helper virus.
Viral RNAs were measured by hybridization to 32P-
pKW101 (v-rel) and 32P-pSW253_ (REV-A). Specific
activities and the size of the probes were taken into
consideration. In the REV-T(REV-A)stock,the titer of
REV-A was 1.5104 IU/ml, while the relative titer of
REV-T was 8X 104 IU/ml. In the REV-T(CSV) stock,
the titer of CSV was 5105 IU/ml, while the relative
titer of REV-T was 1x 105 IU/ml.
Infectious virus present in the plasma samplesof in-
fected chicks was also titrated by endpointdilution onto
SC CEFcultures. The reverse transciptase reaction
usedin this assay has been described by Waite and Allen
(23).
Immunohistochemical Analysis
Antibodies used to distinguish between REV-A and
CSV infection were obtained from Dr. R. L. Witter
(24). The REV-A specific monoclonal antibody, 11C100,
wasused ata final dilution of 1:400, whereas the mono-
clonal antibody capable of detecting both REV-A and
CSV, 11A25, was used at a final dilution of 1:200.
Monoclonal antibodies Hy-19 and Hy-16, which detect
chicken IgM heavy chain and chicken IgG, respec-
tively, were developed in this laboratory.
Cells used in indirect immunofluoresence assays were
washed twice in 10 mM P04, 150 mM NaCl, pH 7.5
(PBS) and resuspended to approximately 10° cells/ml.
To prepare cytospins, 105 cells were centrifuged at
90xg and were fixed briefly in acetone before adding
either Hy-19 or Hy-16 as primary antibody. Slides were
incubated at 4° C. overnight, washed 3 times in cold
PBS, and wiped dry before adding fluorescein-labeled
goat anti-mouse IgG (Kirkegaard & Perry Laborato-
ries, Inc., Gaithersburg, Md.). After a 90 minute incuba-
tion at 4° C., slides were washed 3 times in cold PBS,
mounted in buffered glycerol, and examined byfluores-
cence microscopy. Frozen tissue was embedded in
OCT medium (Lab-Tek Products, Naperville, Il.) and
sectioned on a cryostat at 8 ym. Sections were dried
and fixed in ice cold acetone for 5-10 minutes. Once
dried, slides were stored at —20° C. until use.
Acetone-fixed frozen tissue sections were stained
with Hy-19 and Hy-16 using a peroxidase anti-peroxi-
dase (PAP) technique. Tissues were blocked with 50%
FCSin PBScontaining 0.2% sodium azide and an equal
volume of primary antibody was added. After a 30
minute room temperature (RT) incubation, the slides
were washed in 20 mM Tris, 140 mM NaCl, pH 7.5
(TBS) 3 times for 5 minutes each at RT. After a brief
fixation in 10% neutral buffered formalin, rabbit anti-
mouse antibody (Dakopatts, Santa Barbara, Calif.) was
’ added for a 20 minute incubation. After 3 TBS washes,
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monoclonal mouse PAP (Dakopatts) was added for
another 20 minutes. After 3 TBS washes, the slides were
developed in 3% ammonium acetate, pH 5.5 containing
450 ug/ml diaminobenzidine (Sigma, St. Louis, Mo.)
and 0.0045% H2O». Slides were dried, mounted, and
examined by light microscopy. ‘
Histology
Formalin-fixed samples were embedded in paraffin
for histological examination and sectioned on a micro-
tome at 5 ym. Transformedfollicles were identified as
described previously (25) except that bursae wereseri-
5,028,540
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ally sectioned at 200 ppmintervals throughouttheentire
organ and stained with methyl green pyronin (Sigma)
under conditions specified by the manufacturer. Hema-
toxylin-eosin staining was provided by the university
pathology laboratory.
Analysis of cellular DNA |
Cellular DNA was prepared from red blood cells or
cultured cell lines derived from tumors as previously
described (21). Eco RI and Bgl II enzymes were pur-
chased from Boehringer Mannheim, Indianapolis, Ind.Digestion conditions were as specified by the manufac-
turer. Analysis of DNA by Southern transfer and hy-
bridization conditions have been previously described
(21). pBB12, a plasmid containing a 1300 bp fragment of
gag sequences derived from the Schmidt-Ruppin A
strain of avian sarcomavirus (26) wasutilized to locate
endogenous viral sequences. pKW101, a plasmid con-
taining the 967 bp Eco RI fragmentof v-rel sequences
(27) was provided by Dr. H. Temin and utilized to
locate REV-T-specific integration sites and c-rel se-
quences.
The present invention relates to the following results
involving the earlier-described materials and methods.
ANALYSIS OF REV-A AND CSV INFECTION INTHE SC CHICK
Previous reports indicated that REV-A infection
resulted in immunosuppression and bursal atrophy.
Since CSV was reportedto be less pathogenic than theother non-defective memberof the reticuloendothelio-
sis virus family, we compared the effects of REV-A and
CSVinfection in the SC chick. One day old SC chicks
were infected with 105 IU of either REV-A or CSV.
Hematocrits, organs and plasmas were collected fromchicks at 1, 2, and 4 weeksafter infection to examine the
progression of disease. A comparison of total body
weights indicated that REV-A-infected chicks were
runted relative to control chicks. The comparative data
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there was reduced runting and negligible anemia in the
CSV-infected chick.
Tofurtherdistinguish the effects of these two viruses
on thebursa, sections of infected bursaltissue for histo-
logical and immunohistochemical analysis were pre-
pared. Bursae from four birds infected with either
REV-A or CSV were examined at 1 and 2 weeks after
infection. Hematoxylin-eosin staining of the bursal folli-
cles revealed that a majority (> 80%)of thefollicles in
the REV-A-infected bursa were reduced in size (FIG.
1, A and B). Expansion of the interfollicular cell mass
was evident throughout the organ. The cortico-medul-
lary boundaries of the follicles were aberrant and indi-vidual cells appeared more eosinophilic and vaculolated
with chromatin condensation at the nuclear membrane.This appearanceis characteristic of dead or dying cells.
In contrast, only a minority (< 10%)offollicles in the
CSV-infected bursa were similarly affected so that the
tissue as a whole appeared nearly normal (FIG. 1 C).
Bursae from several REV-A or CSV-infected chicks
were stained to reveal IgM using the PAP assay (FIG.
1, D and E). The normal bursa was characterized by
even staining throughout the tissue with more intense
staining in the medulla. The anti-IgM staining pattern in
REV-A-infected bursae was patchy and irregular with
tissue from birds sacrificed 4 weeks after infection more
obviously affected. In contrast, analysis of CSV-
infected tissue revealed normal distribution of IgM in
the bursa (FIG. 1 F).
As one of the functions of the bursa is to seed the
spleen with IgM positive cells, the functional integrity
of the bursa can be examined by determining the IgM
staining pattern of the spleen. The PAPanalysis, there-
fore, was extended to splenic tissue from normal,
REV-A and CSV-infected 2 week old chicks. In con-
trol spleens, the B lymphocyte areas surrounding the
Schweigger-Seidel sheaths stained positively for IgM
while a few individual plasma cells stained intensely
(FIG. 2 A). In contrast, CSV and ALV-infected spleens
 
are shownin Table I. 40 contained greater numbers ofintensely staining plasma
TABLE I
COMPARISON OF REV-A AND CSV-INFECTED CHICKS*
Time? Birds? Body Wt Spleen Liver Bursa Kidney Heart Thymus Hematocrit
Uninfected
iwk 13 58 g 0.08% 3.6% 0.33% 0.31% 081% ND¢ 37.5%
2 wk 9 103 g 0.12% 2.8% 0.60% 0.31% 0.79% ND 33.4%
4 wk 7 241 g 0.20% 2.4% 0.80% 0.34% 067% 0.25% 33.7%
REV-A-infected
i wk 5 54 2 0.17% 5.0% 0.17% 0.30% 0.70% ND 31.5%
2 wk 9 Teg 0.13%. 3.7% 0.21% 0.30% 0.58% ND 29.3%
4 wk i il7g 0.15% 3.9% 0.22% 0.29% 057% 015% : 18.0%
CSV-infected
1 wk 4 64g 0.14% 43% 0.25% 0.33% 0.72% ND 33.3%2 wk Io 94g 0.16% 3.7% 0.39% 0.33% 0.70% ND 34.3%
4 wk 7 187 g 0.18% 2.8% 0.37% 0.27% 048% 0.19% 30.6%
 
*SC chicks from Hyline were infected on day | after hatch with 105 1U of REV-A or CSV via the jugular vein. Body
weights are expressed as the average weight in grams. Organ weights are represented as the ratio of organ to body
weight x 100. Hematocrits are averages of % packed cell volume.
"The time analysis was performed in weeks after infection.
Number of birds analyzed.
“Not done.
While slight splenomegaly and hepatomegaly were
observed, the bursa exhibited severe atrophy. By 4
weeksafter infection, hematocrit values were low,indi-
cating the presence of anemiain later stages of REV-A
. disease. These findings agreed well with previous obser-
vations of REV-A-induced runting, anemia, and bursal
atrophy (2, 28). In contrast to REV-A infection, the
consequences of CSV infection appeared relatively
minor. Although atrophy of the bursa was detected,
60
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cells (FIG. 2, € and D). This increase in the number of
plasmacells coincides with the appearance ofan active
immune response to virus (29, 30). Germinal centers
were not observed as they require 3 to 4 weeks to de-
velop. In distinct contrast to splenic tissue from ALV
and CSV-infected chicks, REV-A-infected spleens ex-
hibited an IgM staining pattern similar to that of unin-
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fected birds (FIG. 2 B). The absence of an increase in
intensely staining plasma cells in the REV-A-infected
spleen coincided with the morphological atrophy of the
bursa. Our results indicated that REV-A disrupts the
ability of the bursa to seed the spleen with maturing
plasmacells and that this immunosuppressive effect was
distinct from the induction of suppressor T-cell activity
that follows REV-A infection (17) and may berelated
to a diminished ability of REV-A-infected chicks to
mount a humoral response against T-independentanti-
gens (18).
HELPER VIRUS REPLICATION IN BURSAL
LYMPHOCYTES
Thedifferential effects of REV-A and CSV infection
of bursal tissue might result from more extensiverepli-
cation of REV-A in the SC chick. To evaluate this
possibility, the amountof virus present in the plasma of
REV-A and CSV-infected chicks was determined by
end-point dilution. REV-A-infected birds maintained a
viremia of 103 to 104IU/ml of plasma throughoutthe 4
week time period examined, while CSV-infected chicks
had 50 to 500-fold lower levels of virus circulating
during the sameperiod.
TABLEII
VIREMIA IN REV-A AND CSV-INFECTED CHICKS*
 
Virus Time Birds Average Viremia (IU/ml)
REV-A 1 wk 5 1.6 x 104
2 wk 9 1.6 x 1044 wk 4 1.0 x 103
cSV 1 wk 5 5.0 x 1022 wk 10 4.0 x 10?
4 wk 6 2.5 x 10°
*One milliliter of blood was collected from REV-A and CSV-infected chicksat 1,
2, and 4 weeks post infection in I ml Alsever's solution to prevent clotting. Plasma
wascollected aseptically after centrifugation at 800 x g to remove cellular constitu-
ents and stored at —70° C. until use. Plasma samples were assayed for virus by
end-point titration on SC CEF using the assay for reverse transcriptase as an
indicator of virusreplication. Viremias are expressed as averagesin infectious units
per ml.
These results indicate that REV-A infection leads to
greater levels of circulating virus. To evaluate the ex-
tent of viral infection in the bursa, we employed mono-
clonal antibodies to assay frozen sectionsofbursal tissue
for the presenceof viral antigens. As expected, analysis
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bursa. However, a moredetailed and quantitative analy-
sis is necessary to substantiate this hypothesis whichis
not meantto limit the present invention butto clarify it
by a possible mechanism.
VIRUS EXPRESSION IN THE TRANSFORMED
FOLLICLE
REV-A and CSVare known to cause lymphoid leu-
kosis, a disease that is bursal-dependent and character-
ized by the early developmentof a preneoplastic lesion
designated the transformed follicle (25). To examine the
presence of transformedfollicles in REV-A and CSV-
infected bursae, formalin-fixed bursal tissue wasserially
sectioned and stained with methyl green pyronin. No
more than two transformed follicles per bursa were
observed in either REV-A or CSV-infected tissue
(FIG. 4). Data from analysis of ALV-infected chicks
suggests that the maximum numberoftransformed folli-
cles were seen by 4 weeksafter infection (25). Signifi-
cantly, equivalent numbers of transformed follicles
were seen in both infected tissues. This assay was re-
peated using frozen tissue sections and adjacentserial
sections containing transformed follicles were stained
by the PAPassay to detect the presence of viral anti-
gens and IgM. Transformedfollicles from both infected
birds contained viral antigen, indicating that either
REV-Aor CSVreplication can occur within proliferat-
ing bursal lymphocytes without resulting in cell death.
Further, consistent with normal B-lymphocyte func-
tion, these transformed follicles exhibited IgM expres-
sion. Therefore, although REV-A infection resulted in
either destruction or depletion of the bursal population,
it seemed unlikely that this is a direct consequence of
viral replication within bursal lymphocytes.
REV-A AND CSV AS HELPER VIRUSES FOR
REV-T-INDUCED DISEASE
Having established the consequences of REV-A and
CSVinfection in the day old chick, these two viruses
were comparedas helper viruses for REV-T-mediated
tumor induction. One day old SC chicks were infected
with either REV-T(REV-A) or REV-T(CSV)and sac-
tificed at one week. Analysis of body and organ weights
showeda significant increase in spleen and liver weights
 
 
with lIC100, specific for REV-A, detected antigen 45 of birds infected with either REV-T(REV-A) or REV-
only in REV-A-infected tissue (data not shown). The =T(CSV).
TABLE Il
COMPARISON OF REV-T(REV-A) AND
REV-T(CSV)-INFECTED SC CHICKS
Birds Body Wt Spleen Liver Bursa Kidney Heart Thymus Hematocrit
Uninfected
13 58 g 0.08% 36% 0.33% 0.31% 0.81% 0.17% 37.5%
REV-T(REV-A)-infected
13 54g 0.28% 54% 0.20% 0.35% 0.72% 0.11% 29.1%
REV-T(CSV)-infected
10 56g 1.02% 7.2% 0.21% 0.39% 0.75% 0.13% 29.4%
*SC chicks from Hyline were infected with REV-T(REV-A) or REV-T(CSV) on day1 after hatch and
were sacrificed | week later for analysis. Samples for hematocrits were obtained from the wing vein prior
to sacrifice. Body weights are represented as the average weight in grams. Organ weights are expressed as
the ratio of organ to body weight x 100. Hematocrits are averages of % packed cell volume.
analysis with 11A25, a reagent capable of reacting with
both REV-A and CSV,demonstrated that both REV-A
and CSV-infected tissue stained equally (FIG. 3). This
result suggested that despite greaterlevels of circulating
infectious REV-A, there is no difference in the amount
of viral antigen present in bursal tissue infected with
either virus and suggests that increased viral expression
is not the basis for the toxic effect of REV-A on the
65
This increase appeared to correlate with the tumor
mass observed at autopsy. Moreover, REV-T(CSV)-
infected spleens were significantly larger than those
from REV-T(REV-A)-infected birds. There was no
difference in the bursal weights between chicksinfected
with either virus; however, both were decreased in
comparison to uninfected controls. Anemia was ob-
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served in chicks infected with either virus, suggesting
tumor involvement in the bone marrow. Thelarge in-
crease in the size of REV-T(CSV)-infected spleen and
liver suggested. that tumor development resulted from
REV-T infection of a population ofcells that is not
present, or at least less susceptible to infection and pro-
liferation, in the REV-T(REV-A)-infected chicks.
Spleen, liver, bursa, and thymus tissue from infected
birds were analyzed for the presence of tumors. In
order to detect the majority of tumors present in the
affected organs, each tissue was serially sectioned in at
least four distinct areas approximately 200 wm apart and
examined with hematoxylin-eosin, methyl green pyro-
nin, anti-IgM and anti-IgG staining. Six REV-T(REV-
A) and four REV-T(CSV)-infected birds were ana-
lyzed. Dueto the extensive range in size and number of
tumors presentin the affected organs,it was difficult to
quantitate precisely the number of individual tumors
per bird. However, the majority of tumors (~90%)
identified by hematoxylin-eosin staining in the REV-
T(REV-A)-infected liver were negative for IgM ex-
pression, whereas the majority of tumors (~ 90%) in the
REV-T(CSV)-infected liver were positive for IgM
expression (FIG. 5). While analysis of the spleen and
bursa was more difficult due to the background of IgM
positivecells in these organs, the same general observa-
tion was apparent. The numberof tumors present in the
thymus was too few to be informative. None of the
tumors in any tissue were positive for IgG expression.
The difference between the phenotype of these two
tumors was pursued by developing cell lines from
tumortissue. Twenty-seven cell lines were developed
from tumors of 13 REV-T(REV-A)-infected birds and
16 cell lines were made from tumors of 9 REV-T(CSV)-
infected birds. Lines derived from REV-T(REV-A)-
induced tumors were never more than 30% positive for
IgM
_
expression, while lines derived from REV-
T(CSV)-induced tumors were 50 to 100% positive for
IgM expression.
TABLE IV
COMPARISON OF REV-T(REV-A) AND
REV-T(CSV) TUMOR-DERIVED CELL LINES*
 
Numberof Numberof
Phenotype REV-T(REV-A) Lines REV-T(CSV)Lines
Uncloned
IgM — 17 0
1-30% IgM + 10 0
50-100% IgM + 0 15
Cloned
IgM — 34 3
IgM + 0 29
Total Birds? 13 9
Total Uncloned 27 15
Total Cloned 34 32
 
*Tumor tissue from REV-T(REV-A) and REV-T(CSV)-infected birds were
minced with scissors and cultured in Hahn's medium. Cultures were transferred at
1:5 or 1:10 dilutions 24 to 48 hours after the initial plating and passaged every | to
2 days thereafter. Cell lines were assayed for IgM expression after 4 or 5 transfers.
Clones from these lines were established in soft agar and analyzed for IgM expres-
sion after amplification.
The numberofindividual birds from which unclonedcell lines were derived.
Clones from these lines were established in soft agar
and analyzed for IgM and IgG expression. Of 34 REV-
T(REV-A)-generated clonal lines tested, all 34 were
negative for IgM expression. In contrast, of the 32
REV-T(CSV)-induced clonal lines assayed, 29 were
IgM-positive. All of the clones were negative for IgG
expression. Therefore, the cell line analysis correlated
well with the in vivo tumoranalysis showing that REV-
T(REV-A) infection induces primarily IgM-negative
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tumors while REV-T(CSV)infection induces primarily
IgM-positive tumors.
THE REV-T(CSV)-DERIVED IgM POSITIVE
TUMOR CELL CANBE OF BURSALORIGIN
In the dayold chick, the major population of prolifer-
ating B-cells is located within the bursa. Since REV-
T(CSV) infection produced predominately IgM posi-
tive B-cell tumors, it was determined whether or not
bursal lymphocytes could serve as target cells for REV-
T-induced tumors. A bursal repopulation experiment
was performed whichutilized the segregating endoge-
nous viral locus 4 (EV-4) of the SC chick as a marker to
differentiate between donor and recipient cells (26).
EV-4-negative chicks were used as recipients while
EV-4 positive chicks were employed as donors Recipi-
ent SC chicks were treated with cytoxan and repopu-
lated with CSV-infected donor bursal B cells. Five and
a half days later, three morbid recipient birds were
autopsied for the presence of tumors. For eachbird,five
separate tumor nodules from the liver, three separate
portions of the spleen, and a portion each ofbursa and
thymus were removed to preparecell suspensions for
cell line development. A small sample of the liver sus-
pension was assayed for IgM expression by immunoflu-
orescence. In order to minimize selection, uncloned cell
lines were analyzed between the 4th and 6th transfer
following isolation for IgM expression, presence of EV
loci, and viral integration. Analysis of the liver cell
suspensions prepared at isolation showed that all sam-
ples were 50% to 100% positive for IgM. As the liver
suspensions were prepared from tumor nodules and
were probablyclonal, the high percentage of IgM posi-
tive cells was expected. Cell lines grew outofall tissue
samples taken, including the thymus preparations.
Whenthese lines were tested for IgM expression at the
4th transfer, all lines, whether derived from liver,
spleen, bursa, or thymus, were greater than 99% IgM
positive. This result demonstrated that IgM-positive
tumor was presentin all tissues and, therefore, capable
of metastasis and proliferation in multiple microenvir-
onments.
Because helper virus was present in REV-T(CSV),a
spreading infection was established once the infected
bursal cells divided following transplantation. Conse-
quently, the DNAfrom thecell lines had to be analyzed
for the EV-4 locus to positively identify the lines as
being of donororigin. DNA samplesdigested with Eco
RI were analyzed by Southern transfer and hybridiza-
tion with pBB12 to detect EV loci. Eighteen cell lines
from 2 birds were analyzed, along with donor and re-
cipient RBC DNA.Ofthe. 18 lines, 16 had EV-4 loci,
demonstrating they were of donorcell origin (FIG.6).
This experiment demonstrates that REV-T is capable of
infecting cells of bursa! origin and inducing IgM posi-
tive tumors that appearat the time of tumorinitiation to
be both bursal-independent and capableofin vitro pro-
liferation. .
The cell lines were analyzed for unique REV-Tinte-
gration sites to determine whether the tumors from
which these lines were developed were‘identical. DNA
wasdigested with Bgl II which cuts onceinside REV-T
but outside v-rel sequences (31). Bgl II digestion and
hybridization to v-rel, therefore, identifies a single
unique fragment for each exogenous REV-T integra-
tion. The pKW101 rel-specific probe used also hybrid-
izes to three fragments of c-rel (32). When DNA sam-
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ples from the tumor lines were analyzed for rel-specific
sequences, integration specific bands were detected in
every line (FIG. 7). The multiple bands observed in
lines developed from bursal, thymic, and splenic tumor
tissue probably represent multiple, independent tumors
as these cell lines were not cloned. Consistent with this
interpretation, the hybridization of v-rel to the integra-
tion specific fragments is less intense than to fragments
of c-rel (which served as an internal standard for a
single copy gene), indicating significant heterogeneity
in the tumor population. Lines developed from liver
nodules had single integration-specific fragments which
hybridized with intensities equivalent to that of frag-
mentsof c-rel, indicating that these lines were probably
clonal with respect to REV-T integration. Twenty
seven different patterns of integration were found in 29
different lines isolated from 3 birds indicating that mul-
tiple REV-T-infected bursal B-lymphocytes gave rise
to tumorsin this system.
IN VITRO REV-T(CSV) TRANSFORMATION OF
CHICKEN B-CELLS
The results from the in vivo studies described above
were followed by an attempt to transform B-cells in
vitro with REV-T(CSV). In vitro infection could be
used directly to produce isolated clones of permanent
B-cell lines secreting immunoglobulin. Cell suspensions
were isolated from bursa, spleen, bone marrow and
peripheral blood of 3 week old chicks. The cells were
further purified by Ficoll gradient centrifugation. Prep-
arations of these different mononuclearcells containing
108 cells were infected for 30 minutes at 37° C. with
approximately | x5 infectious units of REV-T(CSV)
and the cells seeded in Hahn’s medium (22) in microtiter
trays at 105 cells per well. Four hundred wells were
plated for each infected cell type including bursal,
splenic, bone marrow and peripheral blood. The cells
were incubated at 37° C. in CQ2 for seven to ten days.
Wells that were positive for growth were expanded in
standard growth medium as described above. In no case
were more than 15% of the wells positive for growth.
Each well positive for growth, therefore, could be con-
sidered in clonal! in origin. These clonal outgrowths
were then screened for immunoglobulin production.
Forty-seven of 49 bursal clones were positive for IgM
expression. Twenty-six of 40 splenic clones were posi-
tive for IgM expression. 5 of 12 bone marrow-derived
clones and 3 of 9 peripheral blood-derived clones were
positive for IgM expression. These results demonstrated
that in vitro REV-T(CSV) infection of different
mononuclear cell populations containing B-cell lym-
phocytes leads to clonal proliferation and isolation of
immunoglobulin positive B-cell lines with high effi-
ciency. ‘
This in vitro procedure should work using any v-rel
expressing virus including helper-free REV-T and
REV-T packaged by other helper viruses such as
DIAV, SNV or REV-A variants. The present results
indicate that this procedure works even with REV-A as
a helper virus, though less efficiently. This in vitro
procedure should also be usable following electropora-
tion or transfection of the v-rel gene into these different
lymphocyte populations.
This method could be modified further to increase
both efficiency and productivity by isolating isotype
specific lymphocytes from various anatomical compart-
ments, (e.g. bursa, spleen, gland of Harder, etc.). Fo-
lowing Ficoll gradient centrifugation, selective isola-
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tion of either IgM, IgA or IgG bearing lymphocytes
prior to infection can be achieved by isotypic selective
panning using alpha-IgM,alpha-IgA or alpha-IgG anti-
bodies. This purification would enable preparation of
greater numbersofclones bearing a given immunoglob-
ulin isotype.
A modification of the above-described in vitro
method should increase the efficiency with which
clones producing antigen-specific immunoglobulin are
isolated. In this modification, the REV-T-infected lym-
phocytes would be incubated in vitro in the presence of
the antigen used to immunize the bird (from which the
cells were isolated) prior to plating in Hahn’s medium.
alternatively, the antigen could be bound to the micro-
titer plates in which thecells are plated. This modifica-
tion is based upon the conceptthat the antigen will act
as a specific mitogen for the immunoglobulin positive
cell expressing the antibody specificity for that antigen.
Other molecules that would be mitogenic for these
B-cells would also be added to stimulate growth and
thereby initiate expression of v-rel. Included in the list
of mitogens would be Bcell cytokines as well as anti-
bodies against other cell surface markers such as Ia.
Certain aspects of the present invention maybe dis-
cussed specifically as follows.
HIGH FREQUENCY INDUCTION OF IgM
POSITIVE B-CELL LYMPHOMAS
Results relevant to the present invention and de-
scribed herein demonstrate that by using chicken syncy-
tial virus to provide the helper functions for REV-T
replication, following infection of day old chicks, the
majority of induced tumors express IgM. The tumors
within a single bird were polyclonal, which suggested
that initiation and tumor developmentoccurefficiently
within a numberofcells. The present results also dem-
onstrated that bursal B-cells infected by REV-T(CSV)
were able to develop as a disseminated IgM positive
tumor. Dissemination to a variety of microenviron-
ments occurred without requiring an extended period of
tumorprogression,indicating that the initial tumor was
bursal-independent. These same tumors proliferated
indefinitely as in vitro cell lines. These experiments
provide the first evidence that expression of v-rel can
induce IgM positive B-cell tumors with a high effi-
ciency. Previous studies characterizing in vitro-derived
cell lines with a variety of heterosera, including several
directed against both B and T lymphocytes of the
chicken, have suggested that REV-T(REV-A)induces
a poorly defined lymphoid tumor perhaps within the
B-cell lineage (13-15). The issue of tumor phenotypeis
somewhatconfused as the original tumor was described
as reticuloendothelial perhaps within the macrophage-
dendritic cell lineage (2, 3, 10). Definitive markers capa-
ble of identifying these tumors and relating their pheno-
type to that of a normal cellular compartment have not
yet been identified. In retrospect, it is significant that
two REV-T-induced cell lines expressing IgM have
been isolated (14, 16). Our in situ analysis of tumors
produced following infection with REV-T(REV-A)
revealed that less than 10% of these tumors expressed
IgM. Noneofthe cell lines prepared from these tumors
(isolated on a completely random basis) expressed IgM.
While analysis of tumor tissue has not been reported,
these results are consistent with previous in vitro obser-
vations (13-15). The observations described herein that
altering the helper virus that provides the viral proteins
for REV-Treplication also changes the type of tumor
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induced by v-rel expression appears to be thefirst re-
port of such a phenomenon. Other helper viruses are
able to influence the course of tumor developmentfol-
lowing infection by an acute transforming retrovirus
but the actual type of tumor that develops remains un-
changed. The development of Abelson disease can be
markedly influenced by the specific helper virus with
which the animal is infected but only the incidence and
rate of disease onsetare altered (33). Similarly, the type
of Friend disease is specified by the infecting strain of
SFFV,either SFFV, or SFFV,, as determined by the
different env regions (34). In each instance, different
strains of helper MuLVcan influence the course of the
disease. In contrast to these examples, REV-A and CSV
havea direct influence on the actual type of tumorthat
REV-T induces. As discussed below, this influence
appearsrelated to the cytotoxic effect REV-A replica-
tion has on the IgM positive B-cell population within
the bursa.
REV-A INDUCES EXTENSIVE BURSAL
ATROPHY
Previous work has shown that REV-A induces the
appearanceof a suppressor T cell that correlates with a
state of immunosuppression that is independent of bur-
sal function (17, 18, 35). While the basis for this phe-
nomenon has not been determined, it would appear to
differ from the mechanism by which REV-Ainfluences
the spectrum of REV-T-induced tumors. The IgM neg-
ative tumor induced by REV-T(REV-A) appears to
result from the generalized atrophy that affects the
bursa. The present analyses of the bursa demonstrates
not only that the size of the bursa was reduced but also
that the tissue within this organ was disrupted and the
expression of IgM aberrant. It may be relevant that
acute REV-A infections were knownto be cytotoxic to
fibroblasts in vitro (5). The interfollicular tissue, a po-
tential source of fibroblast and stromal cell-derived
growth factors, was markedly altered. While there was
no direct evidence, it seemedlikely that the B-cell pop-
ulation, which normally undergoes extensive prolifera-
tion and differentiation, had ceased division and was
stationary or dying. Under these conditions, while
REV-T may be able to infect the bursal lymphocyte
population, activation of v-rel expression and tumor
induction would be unlikely. In contrast, while the
bursa in the CSV-infected chick was smaller than in the
uninfected chick, both the follicular structure and the
cells within the follicles appear healthy and normal.It
appeared that CSV enables REV-Tto induce primarily
IgM-positive tumors by not destroying the bursal lym-
phocyte and thereby enlarging the target cell popula-
tion to include proliferating, maturing B-cells.
Further work will be required to elucidate the spe-
cific mechanism by which REV-A exerted its patho-
genic effect on the bursa.Itis significant, however, that
both viruses appeared able to replicate with equal effi-
ciency in bursaltissue as evidenced by the expression of
viral antigen. Furthermore, the expression of REV-A
antigens within bursal lymphocytes did not appear to be
cytotoxic by itself as transformed follicles, equally fre-
quent in both REV-A and CSV-infected chicks, express
suchproteins in roughly equal quantities. It also seemed
unlikely that immune elimination of REV-A-infected
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tissue was responsible for atrophy of the bursa,since at
the height of the humoral response during an ALV
infection, ALV DNA sequences were eliminated rap-
idly from both the bone marrow and the peripheral
white bloodcell population while they were selectively
maintained in the bursa (36). It appears likely that
REV-Ainfection resulted in destruction of the bursal
stroma such that stromallymphocyte interactions and-
/or production ofessential growth factors required for
B-cell proliferation and survival are absent. It was possi-
ble that one of the REV-A glycoproteinsbindsto bursal
cells or a specific growth factor thereby blocking an
interaction required for bursal lymphocyte prolifera-
tion. It has been proposed that a 26 amino acid peptide
found in a numberofretroviral transmembrane glyco-
proteins has immunosuppressive activity (37). A similar
sequence has. been located in gp20 for REV-A (38).
THE TARGET CELL AND V-REL-INDUCED
NEOPLASTIC DISEASE
The observation that REV-T can induce tumors that
are predominantly IgM-positive demonstrates that the
spectrum ofcells in which v-rel is able to induce neo-
plastic disease is larger than originally thought. While
two IgM positive cell lines have been seen before, the
fact that the frequency with which they can be induced
is so dramatically altered by changing the helper virus
illustrates that access to a given cell type playsa signifi-
cant role in defining which cells are target cells for
v-rel-induced tumorigenesis. While access to the IgM
target cell may have been uniquely provided by the
helper virus in this system, a formally similar situation
has been studied with Abelson virus-induced disease.
The rangeof cell phenotypesthat can be transformed in
vitro by A-MuLVincludespre-B, immature and mature
B-lymphocytes, erythroid precursors, macrophages and
mastcells (39-41). Not all of these cells however, serve
as targets in vivo. Pre-B and immature B-lymphocytes
serve as the most frequent target cells for Abelson-
induced tumors (42, 43). In contrast, mast cells and
macrophagesserve astargets infrequently and Abelson-
induced erythroid tumors have not been observed (39,
44). These data support the conclusion that a variety of
factors beyond the ability of expressed v-abl sequences
to function in a permissive environment are important
in determining whether or not a cell serves as a target
for Abelson-induced tumor development.
Defining the range of target cells has important impli-
cations for identifying the cellular genes that are in-
volved in v-rel-mediated tumor development. Ofpartic-
ular interest to this laboratory is the genetic analysis of
B-cell lymphoma developmentin the chicken. The IgM
positive bursal-derived tumor induced by expression of
v-rel differs significantly from the IgM positive bursal
derived tumorisolated following ALV infection. This
ALV-induced tumoris characterized by elevatedlevels
of c-myc resulting from viral integration within the
normal cellular locus (45, 46). While these two tumors
have developed from apparently similar target cells and
appear phenotypically identical, their development, as
outlined in Table V, is quite distinct and indicates that
significant differences exist in the genetic pathways
utilized in the developmentof these two lymphomas.
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TABLE V
COMPARISON OF REV-T(CSV) AND ALV-DERIVED
IgM POSITIVE B-CELL LYMPHOMAS
REV-T(CSV)-Induced ’  ALV-Induced
Develop within 1-2 weeks
Apparentsingle hit kinetics
Nopreneoplastic lesion
Primary tumoris bursal independent
Tumorprogression not required for
metastasis to non-bursalsites
Adaptation to in vitro growth
not required
Multiple hit kinetics
required
A molecular comparison of the sequences expressed
in the two tumors should identify genes that function
specifically in one or the other of the pathways thereby
providing information thatis importantin dissecting the
functions of v-rel and c-myc during neoplastic develop-
ment in the avian B-lymphocyte.
The present invention involves the effects of both
REV-A and CSV infection on bursal tissue. REV-A
infection resulted in bursal atrophy, destroying both its
structural and functional integrity. In contrast, the
bursa in CSV-infected chicks, while reduced slightly in
size, appeared both structurally and functionally nor-
mal. REV-A-induced bursa! atrophy was not a result of
viral replication in the B-lymphocyteas: (i) both viruses
were capable of inducing, with equal efficiency, the
formation of preneoplastic lesions containing proliferat-
ing B-lymphocytes; and,(ii) it appeared that equivalent
amountsofviral antigen were expressed in the bursa of
chicks infected with either virus.
In REV-T(REV-A)-infected chicks, the majority of
tumors that developed were negative for IgM expres-
sion. In contrast the majority of tumors induced by
REV-T(CSV)infection were IgM positive. This find-
ing was confirmed by recovery of IgM negative cell
lines from REV-T(REV-A)-infected chicks and IgM
positive cell lines from REV-T(CSV)-infected chicks.
In addition, repopulation studies showed that IgM-posi-
tive bursal-derived cells served as target cells for
REV(CSV)-induced lymphomas. REV-T can induce
IgM-positive B-cell lymphomas with high efficiency.
Infections by the helper viruses, REV-A and CSV,
differ dramatically in their effects on the composition of
the population of cells that serve as targets for REV-T-
induced neoplasia.
There are several advantages in using the chicken to
produce monoclonai antibodies. At least four specific
exemplary types of monoclonals isolated from the
chicken would besignificant value.
a) Many human antigens are not seen by the mouse
because they are highly conserved between man
and mouse. Since the chicken is phylogenetically
Indentifiable preneoplastic lesion
Primary tumoris bursal dependent
Tumorprogression required for
metastasis to non-bursal sites
Adaptation to in vitro growth
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more distant from man, a significant number of .
chickens monoclonals should be developed against
important human antigens.
b) Many mouseantigensare traditionally recognized
by allotypic heterosera. These antisera are fre-
quently weak and difficult to produce. Other anti-
gens, of course, have not been recognized because
they are identical in the immunized mouse. Both
sets of antigens would be excellent candidates for
recognition by the chicken monoclonals.
c) Several important avian pathogens are of enor-
mous economic significance. Defining the epitopes
seen by the chicken during infection with these
65
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Development requires 3-6 months
pathogensby using avian monoclonals would heip
in developing effective vaccinestrategies.
d) In many cases tumor specific antigens found on
avian tumors should be recognized by the chicken.
This set of antigens has potential for understanding
tumor regression in several avian systems.
Citations in the following list are incorporated by
reference herein for the reasonscited.
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Changes may be madein the construction, operation
and arrangement of the various parts, elements, steps
and procedures described herein without departing
from the concept and scope of the invention as defined
in the following claims.
Whatis claimedis:
1. A method for preparing antibody-producing avian
cell clones specific for a desired antigen, the method
comprising:
immunizing a bird with a desired antigen;
separating a population of antibody-producing B-
lymphocytes from said bird;
treating said antibody-producing B-lymphocyte pop-
ulation in vitro with v-rel under conditions induc-
ing transformation; and
incubating said v-rel-treated B-lymphocyte popula-
tion in vitro under conditions facilitating prolifera-
tion of antibody-producing B-lymphocytes trans-
_ formed byv-rel.
2. A method of preparing antibody-producing avian
cell clones specific for a desired antigen, the method
comprising:
immunizing a bird with a desired antigen;
separating a population of antibody-producing B-
lymphocytes from said bird;
treating said antibody-producing lymphocyte popula-
tion in vitro with reticuloendotheliosis virus and a
non-cytotoxic avian helper virus to induce cell
transformation; and
incubating said treated B-lymphocyte population in
vitro under conditions facilitating proliferation of
transformed antibody-producing B-lymphocytes.
3. A method for preparing antibody-producing avian
cell clones specific for a desired antigen, the method
comprising:
immunizing a first bird with a desired antigen;
separating a population of antibody-producing B-
lymphocytes from thefirst bird;
treating said antibody-producing B-lymphocyte pop-
ulation in vitro with v-rel to produce transformed
antibody-producing B-lymphocytes;
transplanting said treated B-lymphocytes into a sec-
ond bird, the second bird having been pretreated to
remove normal B-lymphocytes, and allowing
transformed B-lymphocytes to proliferate in the
second bird; and
isolating said transformed antibody-producing B-
lymphocytes from the secondbird.
4. The methodof claim 1 or 2 wherein the incubating
step comprises treatment of the treated B-lymphocyte
population with the desired antigen and subsequent
plating in microtiter plates.
5. The method of claim 1 or 2 wherein the incubating
step comprises incubation of the treated B-lymphocyte
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population in culture medium comprising the desired
antigen.
6. The method ofclaim 1 or 2 wherein the incubating
step comprises incubation of the treated B-lymphocyte
population in culture medium comprising B-cell mito-
gens.
7. The methodofclaim 6 wherein the B-cell mitogens
are one or moreoflectins, cytokines and antibodies
directed against B-lymphocyte surface proteins.
8. The methodofclaims1, 2, 3 wherein the separating
involves panning said antibody-producing B-lym-
phocytes on solid surface comprising bound antibodies
having binding specificity for avian IgM.
9. The method of claims 1, 2, 3 wherein the popula-
tion of antibody-producing B-lymphocytesis separated
from bursa, spleen, bone marrow, gland of Harder,
intestinal lining or peripheral blood of the bird.
10. The method of claim 1 or 3 wherein the v-rel is
included in a reticuloendotheliosis virus.
11. The method of claim 1, 2, 3 or wherein the bird is
a chicken.
12. The method of claim 1 or 3 wherein the treating
step involves transfection with a v-rel gene.
13. The method of claim 1 or 3 wherein the treating
step involves electroporation.
14, The method of claim 1, 2, 3 or wherein the anti-
body producedis of an IgM isotype.
15. The method of claim 2 wherein the reticuloendo-
theliosis virus with a non-cytotoxic helper virus is
REV-T(CSV).
16. The method of claim 2 wherein the helpervirusis
chick syncytial virus, spleen necrosis virus (SNV), at-
tenuated REV-A or duck infectious anemia virus
(DIAV).
17. The method of claim 1 or 2 wherein the incubat-
ing step involves plating cells out in microtiter plates.
18. The method of claim 1 or 2 wherein the incubat-
ing step involves cell culturing in microtiter plates for a
period of at least about one week.
19. The method of claim 1 or 2 wherein the bird i s
between about six weeks and two yearsofage.
20. The method of claim 1, 2, 3 or wherein the immu-
nization is monitored by routine serological analysis.
21. The methodofclaim 1, 2, 3 or wherein the immu-
nization is indicated by measurement of an antibody
titer greater than about 1/200.
22.The methodofclaim 1, 2, 3 or wherein the separa-
tion of antibody-producing B-lymphocytes involves
centrifugation in a density gradient comprising polysac-
charide.
23. The method of claim 1 or 2 wherein anisolating
step involving plating out transformed B-lymphocytes,
follows the incubating step.
24. The method of claim 1 or 2 wherein anisolating
step involving selecting cell clones producing antibody
directed against the desired antigen, follows the incu-
bating step.
25. The method ofclaim 1 or 2 wherein an isolating
step involving panning said transformed B-lymphocytes
on a solid surface comprising a bound second antibody
having a specific binding specificity for an avian anti-
body, follows the incubating step.
* * * * *
